Dr. Kiyoshi Shiga: Discoverer of the dysentery bacillus

Clinical Infectious Diseases

Volumn 29, Issue 5, 1999, Pages 1303-1306

  Trofa, Andrew F ^a,b   Ueno Olsen, Hannah ^c   Oiwa, Ruiko ^d   Yoshikawa, Masanosuke ^e  

^a South Jersey Infectious Disease   (United States)

^b Department of Arts and Humanities ^*  (United States)

^c RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

^d KITASATO UNIVERSITY   (Japan)

^e NIPPON DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DYSENTERY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHIGELLA DYSENTERIAE;

DYSENTERY, BACILLARY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; JAPAN;

EID: 0033496732     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313437     Document Type: Review

References (34)

1. 1. Shiga K. The trend of prevention, therapy, and epidemiology of dysentery since the discovery of its causative organism. N Engl J Med 1936;215: 1205-11.
2. 2. Institute of Medicine. The prospect for immunizing against Shigella species. New vaccine development: establishing priorities. Vol. 2. Diseases of importance in developing countries. Washington, DC: National Academy Press, 1986.
3. 3. DuPont HL, Gangarosa EJ, Reller LB, et al. Shigellosis in custodial institutions. Am J Epidemiol 1970;92:172-9.
4. 4. Grant AK, Purser BN, Hazel JR. Shigella flexneri dysentery in the Australian forces in South Vietnam. Med J Aust 1969;2(15):752-5.
5. 5. Hyams KC, Bourgeois AL, Merrell BR, et al. Diarrheal disease during Operation Desert Shield. N Engl J Med 1991;325:1423-8.
6. 6. Mata LJ, Gangarosa EJ, Caceres A, et al. Epidemic Shiga bacillus dysentery in Central America. I. Etiologic investigations in Guatemala, 1969, J Infect Dis 1970;122:170-80.
7. 7. Ries A, Wells JG, Olivola D, et al. Epidemic Shigella dysenteriae type 1 in Burundi; panresistance and implications for prevention. J Infect Dis 1994;169:1035-41.
8. 8. Shears P. Shigella infections. Ann Trop Med Parasitol 1996;90:105-14.
9. 9. Lindberg AA, Pal T. Strategies for the development of potential candidate Shigella vaccines. Vaccine 1993;11:168-79.
10. 10. Cohen D, Ashkenazi S. An update on Shigella vaccines. Isr J Med Sci 1994;30: 495-7.
11. 11. Behring E, Kitasato S. Ueber das Zustandkommen der Diphtherie-Immunitaet und der Tetanus-Immunitaet bei Thieren. Dtsch Med Wochenschr 1890;49:1-6.
12. 12. Kitasato S. The bacillus of bubonic plague. Lancet 1894;2:428-30.
13. 13. Zinsser H, Bayne-Jones S. A textbook of bacteriology. 8th ed, New York: D. Appleton Century, 1939:538-42.
14. 14. Dupont HL. Shigella species (bacillary dysentery). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2033-9.
15. 15. Shiga K. Observations on the epidemiology of dysentery in Japan. Philippine Journal of Science 1906;1:485-500.
16. 16. Shiga K. Ueber den Erreger der Dysenterie in Japan, Vorläufige Mitteilung. Zentralbl Bakteriol Microbiol Hyg 1898;23:599-600.
17. 17. Flexner S. On the etiology of tropical dysentery, Philadelphia Medical Journal 1900;6:414-21.
18. 18. Keusch GT. The rediscovery of Shiga toxin and its role in clinical disease. Jpn J Med Sci Biol 1998;51(Suppl 1):S5-22.
19. 19. Bergey's manual of determinative bacteriology. 3rd ed. Baltimore: Williams & Wilkins, 1930:357-63.
20. 20. Bergey's manual of systematic bacteriology, Vol I, 9th ed. Baltimore: Williams & Wilkins, 1984:423-7.
21. 21. Shiga K. Kiyosuiso Kanwa. Tokyo: Nihon Iji Shimpo Shuppan-bu, 1950.
22. 22. DuPont HL, Hornick RB, Dawkins AT, et al. The response of man to virulent Shigella flexneri 2a. J Infect Dis 1969;119:296-9.
23. 23. DuPont HL, Levine MM, Hornick RB, et al. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159:1126-8.
24. 24. Kopecko DJ, Baron LS, Buysee J. Genetic determinants of virulence in Shigella and dysenteric strains of Escherichia coli: their involvement in the pathogenesis of dysentery. Curr Top Microbiol Immunol 1985;118:71-95.
25. 25. Yoshikawa M, Sasakawa C. Molecular pathogenesis of shigellosis: a review. Microbiol Immunol 1991;35:809-24.
26. 26. Hale TL. Genetic basis of virulence in Shigella species, Microbiol Rev 1991;55:206-24.
27. 27. Chu C, Liu B, Watson B, et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type I (Shiga's bacillus) bound to tetanus toxoid. Infect Immun 1991;59:4450-8.
28. 28. Taylor DN, Trofa A, Sadoff J, et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of O-specific polysaccharides of Shigella dysenteriae type I, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993;61:3678-87.
29. 29. Li A, Karnell A, Huan PT, et al. Safety and immunogenicity of the live oral, auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine 1993;11:180-9.
30. 30. Yoshikawa M, Sasakawa C, Okada N, et al. Construction and evaluation of a virG thy A double mutant of Shigella flexneri 2a as a candidate live-attenuated oral vaccine. Vaccine 1995;13:1436-40.
31. 31. Phalipon A, Sansonetti P. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Biologicals 1995;23:125-34.
32. 32. Noriega FR, Losonsky G, Lauderbaugh C, et al. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect Immun 1996;64:3055-61.
33. 33. Klee SR. Construction and characterization of a live, attenuated vaccine candidate against Shigella dysenteriae type I. Infect Immun 1997;65: 2112-8.
34. 34. Obituary. The New York Times 1957 26 Jan, sec. 19:6.